Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NTRB 
Nutriband Inc (NTRB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: NTRB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15
1 Year Target Price $15
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.99% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.91M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 1 | Beta 1.29 | 52 Weeks Range 3.72 - 11.78 | Updated Date 09/15/2025 |
52 Weeks Range 3.72 - 11.78 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.72 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -321.83% |
Management Effectiveness
Return on Assets (TTM) -35.74% | Return on Equity (TTM) -98% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 79192534 | Price to Sales(TTM) 33.33 |
Enterprise Value 79192534 | Price to Sales(TTM) 33.33 | ||
Enterprise Value to Revenue 30.72 | Enterprise Value to EBITDA -4.55 | Shares Outstanding 12016000 | Shares Floating 3982818 |
Shares Outstanding 12016000 | Shares Floating 3982818 | ||
Percent Insiders 70.78 | Percent Institutions 2.89 |
Upturn AI SWOT
Nutriband Inc
Company Overview
History and Background
Nutriband Inc. focuses on transdermal drug delivery systems. Its history involves the development and commercialization of abuse-deterrent transdermal technologies and nutraceutical products. The company has evolved from focusing solely on abuse-deterrent formulations to expanding into broader transdermal delivery applications.
Core Business Areas
- Abuse-Deterrent Transdermal Technology: Development and licensing of AVERSA abuse-deterrent technology designed to prevent opioid abuse through transdermal patches.
- Nutraceutical Products: Development and sale of transdermal nutraceutical patches for various health and wellness applications.
Leadership and Structure
The leadership team comprises executives with experience in pharmaceuticals, technology, and finance. The organizational structure is typical of a small cap company, likely with functional departments focused on R&D, sales, and operations.
Top Products and Market Share
Key Offerings
- AVERSA Technology: Abuse-deterrent transdermal patch technology. The market share is still emerging and dependent on licensing agreements and regulatory approvals. Competitors include companies developing other abuse-deterrent formulations, such as Collegium Pharmaceutical (COLL) and Teva Pharmaceutical (TEVA).
- Nutraceutical Patches: Transdermal patches delivering vitamins and supplements. Market share is relatively small in the overall nutraceutical market. Competitors include companies like MaryRuth Organics, Garden of Life, and other transdermal patch manufacturers. Revenue data is not publicly specified.
Market Dynamics
Industry Overview
The pharmaceutical and nutraceutical industries are highly competitive and regulated. The transdermal drug delivery market is growing, driven by patient preference for non-oral routes of administration and technological advancements.
Positioning
Nutriband Inc. is positioned as an innovator in transdermal drug delivery, particularly in abuse-deterrent formulations. Their competitive advantage lies in their patented AVERSA technology.
Total Addressable Market (TAM)
The total addressable market for transdermal drug delivery is projected to reach billions of dollars. Nutriband's positioning within the abuse-deterrent segment gives them access to a specific, high-need area, but requires successful licensing and partnerships to fully realize TAM.
Upturn SWOT Analysis
Strengths
- Patented AVERSA technology
- Focus on abuse-deterrent formulations
- Potential for licensing revenue
- Expanding into nutraceutical products
Weaknesses
- Limited financial resources
- Dependence on licensing agreements
- Small market share in nutraceuticals
- Regulatory hurdles for pharmaceutical products
Opportunities
- Growing demand for abuse-deterrent formulations
- Expansion into new nutraceutical markets
- Partnerships with pharmaceutical companies
- Technological advancements in transdermal delivery
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes
- Patent infringement
- Failure to secure licensing agreements
Competitors and Market Share
Key Competitors
- COLL
- TEVA
- ALKS
Competitive Landscape
Nutriband Inc. is a smaller player compared to larger pharmaceutical companies. Its advantage lies in its specialized technology, but it faces challenges in competing with companies with greater resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on licensing agreements and product development milestones.
Future Projections: Future growth is projected to be driven by successful commercialization of AVERSA technology and expansion in the nutraceutical market. Analyst estimates are not widely available due to the company's size.
Recent Initiatives: Recent initiatives include pursuing partnerships with pharmaceutical companies and expanding the nutraceutical product line.
Summary
Nutriband Inc. is a small cap company with a unique technology in the abuse-deterrent transdermal patch market. Its AVERSA technology provides a potential competitive advantage, but financial resources are limited and the reliance on partnerships for revenue generation poses risks. The company's future success hinges on its ability to secure licensing agreements and expand its nutraceutical offerings effectively. There are significant risks associated with a company of this size.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company website
- Industry reports
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own research and due diligence. Market share is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nutriband Inc
Exchange NASDAQ | Headquaters Orlando, FL, United States | ||
IPO Launch date 2017-11-30 | Founder, Acting CEO, President, Company Secretary & Executive Chairman of the Board Mr. Serguei Melnik | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nutriband.com |
Full time employees - | Website https://www.nutriband.com | ||
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.